This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Prothena (PRTA) Up 78.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Moves 5.9% Higher: Will This Strength Last?
by Zacks Equity Research
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?
by Zacks Equity Research
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.
Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 7.23% and 80.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Prothena (PRTA) Down 19.9% Since Last Earnings Report?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -13.24% and -70.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II
by Zacks Equity Research
Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.
Prothena (PRTA) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session
by Zacks Equity Research
Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
Options Traders Expect Huge Moves in Prothena (PRTA) Stock
by Zacks Equity Research
Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.